Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 EBITDA Margin % is 23.99% as of Jun. 2026, which is 7% below its 10-year median of 25.86. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 958 Drug Manufacturers companies, Essex Bio-Technology ranks better than 80.17% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Essex Bio-Technology EBITDA Margin % Related Terms
Essex Bio-Technology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essex Bio-Technology (HKSE:01061) has a EBITDA Margin % of 23.99% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Essex Bio-Technology and its competitors. This is near median its historical median of 25.86. Over the past decade, Essex Bio-Technology's EBITDA Margin % has ranged from 23.81 to 30.21. According to the industry distribution chart, Essex Bio-Technology ranks #190 out of 958 companies in the Drug Manufacturers industry, placing it in the top 19.8%.
Is Essex Bio-Technology's EBITDA Margin % too high?
Essex Bio-Technology's current EBITDA Margin % of 23.99% is near median its 10-year median of 25.86. Over the past 10 years, this metric has ranged from a low of 23.81 to a high of 30.21. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Essex Bio-Technology's value of 23.99% is 92.7% above this industry median. Based on the distribution chart, Essex Bio-Technology ranks #190 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #190 out of 958 companies for EBITDA Margin %. This places Essex Bio-Technology in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.45. Essex Bio-Technology's value of 23.99% is 92.7% above this benchmark. Historically, Essex Bio-Technology's own EBITDA Margin % has ranged from 23.81 to 30.21 over the past decade. While the company's 10-year median is 25.86 vs. the industry median of 12.45, Essex Bio-Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current EBITDA Margin % of 23.99% is 92.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current EBITDA Margin % is 23.99%, which is near median its own 10-year median of 25.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current EBITDA Margin % is 23.99%, which is near median its 10-year median of 25.86 and 92.7% above the Drug Manufacturers industry median of 12.45. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current EBITDA Margin % is 23.99% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
EBITDA Margin %: 23.99% (near median its 10-year median of 25.86)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 92.7% above the Drug Manufacturers median (#190 of 958)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
